Literature DB >> 10501210

Alpha4 but not alpha3 and alpha7 nicotinic acetylcholine receptor subunits are lost from the temporal cortex in Alzheimer's disease.

C M Martin-Ruiz1, J A Court, E Molnar, M Lee, C Gotti, A Mamalaki, T Tsouloufis, S Tzartos, C Ballard, R H Perry, E K Perry.   

Abstract

Neuronal nicotinic acetylcholine receptors labelled with tritiated agonists are reduced in the cerebral cortex in Alzheimer's disease (AD), but to date it has not been demonstrated which nicotinic receptor subunits contribute to this deficit. In the present study, autopsy tissue from the temporal cortex of 14 AD cases and 15 age-matched control subjects was compared using immunoblotting with antibodies against recombinant peptides specific for alpha3, alpha4, and alpha7 subunits, in conjunction with [3H]epibatidine binding. Antibodies to alpha3, alpha4, and alpha7 produced one major band on western blots at 59, 51, and 57 kDa, respectively. [3H]Epibatidine binding and alpha4-like immunoreactivity (using antibodies against the extracellular domain and cytoplasmic loop of the alpha4 subunit) were reduced in AD cases compared with control subjects (p < 0.02) and with a subgroup of control subjects (n = 9) who did not smoke prior to death (p < 0.05) for the former two parameters. [3H]Epibatidine binding and cytoplasmic alpha4-like immunoreactivity were significantly elevated in a subgroup of control subjects (n = 4) known to have smoked prior to death (p < 0.05). There were no significant changes in alpha3- or alpha7-like immunoreactivity associated with AD or tobacco use. The selective involvement of alpha4 has implications for understanding the role of nicotinic receptors in AD and potential therapeutic targets.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10501210     DOI: 10.1046/j.1471-4159.1999.0731635.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  31 in total

1.  A novel angiogenic pathway mediated by non-neuronal nicotinic acetylcholine receptors.

Authors:  Christopher Heeschen; Michael Weis; Alexandra Aicher; Stefanie Dimmeler; John P Cooke
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 2.  Normal genetic variation, cognition, and aging.

Authors:  P M Greenwood; Raja Parasuraman
Journal:  Behav Cogn Neurosci Rev       Date:  2003-12

3.  Synthesis and positron emission tomography studies of C-11-labeled isotopomers and metabolites of GTS-21, a partial alpha7 nicotinic cholinergic agonist drug.

Authors:  Sung Won Kim; Yu-Shin Ding; David Alexoff; Vinal Patel; Jean Logan; Kuo-Shyan Lin; Colleen Shea; Lisa Muench; Youwen Xu; Pauline Carter; Payton King; Jasmine R Constanzo; James A Ciaccio; Joanna S Fowler
Journal:  Nucl Med Biol       Date:  2007-07       Impact factor: 2.408

Review 4.  Nicotinic ACh receptors as therapeutic targets in CNS disorders.

Authors:  Kelly T Dineley; Anshul A Pandya; Jerrel L Yakel
Journal:  Trends Pharmacol Sci       Date:  2015-01-29       Impact factor: 14.819

5.  An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants.

Authors:  Christopher G Baddick; Michael J Marks
Journal:  Biochem Pharmacol       Date:  2011-05-10       Impact factor: 5.858

Review 6.  Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.

Authors:  Kentaro Hirao; Gregory M Pontone; Gwenn S Smith
Journal:  Neurosci Biobehav Rev       Date:  2014-11-20       Impact factor: 8.989

7.  Neurogenetic effects on cognition in aging brains: a window of opportunity for intervention?

Authors:  Ivar Reinvang; Ian J Deary; Anders M Fjell; Vidar M Steen; Thomas Espeseth; Raja Parasuraman
Journal:  Front Aging Neurosci       Date:  2010-11-02       Impact factor: 5.750

Review 8.  Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy.

Authors:  David G Wilkinson; Paul T Francis; Elias Schwam; Jennifer Payne-Parrish
Journal:  Drugs Aging       Date:  2004       Impact factor: 3.923

9.  alpha4beta2-nicotinic receptor binding with 5-IA in Alzheimer's disease: methods of scan analysis.

Authors:  Emma Terrière; Mike Sharman; Claire Donaghey; Lucie Herrmann; Jane Lonie; Marion Strachan; Nadine Dougall; Jonathan Best; Klaus P Ebmeier; Sally Pimlott; Jim Patterson; David Wyper
Journal:  Neurochem Res       Date:  2007-10-25       Impact factor: 3.996

10.  Cortical alpha7 nicotinic acetylcholine receptor and beta-amyloid levels in early Alzheimer disease.

Authors:  Milos D Ikonomovic; Lynn Wecker; Eric E Abrahamson; Joanne Wuu; Scott E Counts; Stephen D Ginsberg; Elliott J Mufson; Steven T Dekosky
Journal:  Arch Neurol       Date:  2009-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.